Actively Recruiting
SBRT vs. Conventional Fractionation With HDR Boost for Prostate Cancer
Led by Dr. Gerard Morton · Updated on 2023-04-12
55
Participants Needed
1
Research Sites
365 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Random assignment between SBRT and conventionally fractionated boost following HDR brachytherapy for prostate cancer.
CONDITIONS
Official Title
SBRT vs. Conventional Fractionation With HDR Boost for Prostate Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 or older
- Completed informed consent for treatment and study participation
- Pathologically confirmed diagnosis of prostate adenocarcinoma
- ECOG Performance Status of 0 to 2
- No prior pelvic radiotherapy, brachytherapy, cryosurgery, HIFU, TURP, or radical prostatectomy
You will not qualify if you...
- Evidence of nodal or distant metastasis on staging MRI or CT Abdomen/Pelvis and Bone scan within 90 days before enrollment (if clinically indicated)
- Planned adjuvant chemotherapy after radiotherapy
- Serious medical conditions or contraindications to HDR brachytherapy
- Presence of inflammatory bowel disease
- Presence of connective tissue disorder contraindicating radiotherapy
- Medically unfit for general or spinal anesthesia
- Unable or unwilling to complete study questionnaires
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada, M4N 3M5
Actively Recruiting
Research Team
G
Gerard Morton, MD
CONTACT
M
Merrylee McGuffin
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here